Company Overview
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.20.
Recent Developments
- Dec 2025 Revenue of $190.00K (-19.1% YoY); net profit $-74.12M.
- Trailing 12 Months Year-on-year growth — revenue -19.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -12.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -12.45% |
| 1 Year: | -19.15% |
Stock Price Performance
| 1 Year: | -90.34% |
| 6 Months: | -21.77% |
| 3 Months: | -36.47% |
| 1 Month: | +21.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -12.4% CAGR over 5 years.
- Trading 91.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATYR aTyr Pharma, Inc. R2K | 0.53 | -0.72 | $51.97M | 0.00% | -99.71% | -105.63% | -12.45% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 94.00K | 184.00K | - | 8.06M | 189.00K | 148.00K | - | - | - | - | - | 0 | 0 | 0 | 353.00K | 235.00K | 0 | 0 | 0 | 0 | 190.00K | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.77M | 20.31M | 26.93M | 14.80M | 11.44M |
| Operating Income | -8.92M | -10.90M | -11.31M | - | -16.11M | -15.43M | -13.87M | - | -13.21M | -11.91M | -10.83M | - | -10.22M | -9.96M | -6.68M | - | -5.88M | -5.64M | -5.50M | - | 1.86M | -6.32M | -6.51M | -7.20M | -10.45M | -7.73M | -12.38M | -12.58M | -13.49M | -12.79M | -13.56M | -12.62M | -16.64M | -17.32M | -18.14M | -15.77M | -20.31M | -26.75M | -14.80M | -11.44M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.39M | -19.93M | -26.36M | -14.40M | -11.04M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.88M | -19.53M | -25.75M | -13.96M | -10.79M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -9.07M | -11.08M | -11.33M | -16.49M | -16.09M | -15.38M | -13.82M | -12.57M | -13.40M | -12.14M | -11.19M | -11.47M | -10.67M | -10.41M | -7.11M | -6.32M | -6.14M | -5.85M | -5.64M | -5.97M | 1.75M | -6.45M | -6.60M | -7.15M | -10.39M | -7.67M | -12.15M | -12.42M | -13.24M | -11.95M | -12.34M | -11.34M | -15.49M | -16.31M | -17.26M | -14.88M | -19.53M | -25.74M | -13.96M | -10.79M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.54 | - | - | - | 0.25 | - | - | -0.51 | -0.64 | -0.42 | -0.44 | -0.44 | -0.46 | -0.29 | -0.22 | -0.20 | -0.23 | -0.23 | -0.23 | -0.17 | -0.22 | -0.26 | -0.14 | -0.11 |
| R&D Expense | 6.59M | 7.50M | 7.74M | - | 12.00M | 11.31M | 10.39M | - | 9.20M | 8.42M | 7.13M | - | 6.15M | 6.48M | 4.20M | - | 3.35M | 3.31M | 3.80M | - | 3.62M | 4.36M | 4.62M | 4.52M | 7.66M | 5.14M | 8.90M | 9.13M | 9.87M | 9.38M | 9.84M | 10.32M | 13.36M | 13.97M | 14.81M | 11.81M | 15.38M | 22.13M | - | 7.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 422.00K | 10.46M | 0 | 10.39M | 353.00K | 235.00K | 190.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 56.79M | 55.27M | 68.15M | 77.82M |
| Operating Income | -19.54M | -23.55M | -47.62M | -57.94M | -47.15M | -32.82M | -22.98M | -15.91M | -34.02M | -46.40M | -54.92M | -67.91M | -77.63M |
| EBITDA | - | - | - | - | - | - | - | - | - | -44.71M | -52.18M | -66.37M | -76.07M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | -45.34M | -50.40M | -64.02M | -74.12M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -20.01M | -24.35M | -47.97M | -57.85M | -48.21M | -34.52M | -16.22M | -16.22M | -33.77M | -45.34M | -50.39M | -64.02M | -74.12M |
| Diluted EPS | - | - | - | - | - | - | - | -1.77 | -1.77 | -1.60 | -0.94 | -0.86 | -0.80 |
| R&D Expense | 13.83M | 16.78M | 34.50M | 42.85M | 30.07M | 20.39M | 14.05M | 17.29M | 23.26M | 42.81M | 42.29M | 54.37M | 60.22M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 20.64M | 129.68M | 80.52M | 89.36M | 52.75M | 36.19M | 38.73M | - | 95.79M | 120.65M | 96.83M | 93.00M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 80.87M | 102.99M | 81.95M | 80.24M |
| Cash & Equivalents | 3.67M | 36.46M | 13.90M | 53.02M | 38.39M | 21.09M | 22.96M | 9.21M | 16.95M | - | 9.98M | 22.54M | 11.05M | 10.74M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 11.78M | 2.44M | 1.74M | 873.00K |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | 24.50M | 30.18M | 27.00M | 25.71M |
| Current Liabilities | - | - | 10.11M | 12.15M | 8.53M | 10.39M | 10.83M | 12.92M | 5.86M | - | 13.86M | 16.42M | 14.97M | 15.15M |
| Long Term Debt | - | - | - | 1.78M | 9.20M | 14.72M | 8.26M | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 11.53M | 15.10M | 13.28M | 12.03M |
| Total Equity | -64.55M | -66.08M | -91.01M | 115.05M | 62.80M | 64.25M | 33.65M | 21.19M | 31.65M | - | 71.46M | 90.66M | 70.02M | 67.48M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 29.50M | 63.29M | 84.04M | 98.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -52.86M | -42.36M | -31.06M | -20.01M | -15.30M | - | -41.89M | -33.22M | -69.12M | -61.99M |
| Investing Cash Flow | - | - | - | 33.53M | -27.64M | 37.17M | 4.92M | 6.90M | - | 47.24M | -20.13M | 17.23M | -5.05M |
| Financing Cash Flow | - | - | - | 4.70M | 52.70M | -4.24M | 1.34M | 16.14M | - | 5.45M | 66.23M | 39.86M | 66.01M |
| Capital Expenditure | -644.00K | -249.00K | -664.00K | -600.00K | -1.31M | -594.00K | -79.00K | -202.00K | - | -1.64M | -4.21M | -65.00K | -77.00K |
| Free Cash Flow | - | - | - | -53.46M | -43.68M | -31.66M | -20.09M | -15.50M | - | -43.53M | -37.44M | -69.18M | -62.06M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 10.81M | 12.88M | -12.02M | -1.03M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | -5,445.0% | -152.2% | - | -446.8% | -15,557.8% | -28,899.6% | -40,856.3% |
| Net Margin % | - | - | - | - | - | - | -3,844.5% | -155.2% | - | -436.5% | -14,274.5% | -27,243.8% | -39,009.5% |
| ROE % | 30.3% | 26.8% | -41.7% | -92.1% | -75.0% | -102.6% | -76.6% | -51.3% | - | -63.4% | -55.6% | -91.4% | -109.8% |
| ROCE % | - | -223.7% | -40.5% | -80.5% | -59.7% | -78.3% | -98.8% | -48.4% | - | -56.6% | -52.7% | -83.0% | -99.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 15.00% | 14.71M | $7.15M |
| 2 | Federated Hermes, Inc. | 10.72% | 10.51M | $5.11M |
| 3 | Blackrock Inc. | 6.57% | 6.44M | $3.13M |
| 4 | UBS Group AG | 3.94% | 3.87M | $1.88M |
| 5 | Vanguard Capital Management LLC | 3.89% | 3.81M | $1.85M |
| 6 | Geode Capital Management, LLC | 2.43% | 2.39M | $1.16M |
| 7 | State Street Corporation | 1.79% | 1.75M | $852.64K |
| 8 | GSA Capital Partners LLP | 1.72% | 1.68M | $818.71K |
| 9 | Millennium Management Llc | 1.67% | 1.64M | $797.64K |
| 10 | Morgan Stanley | 1.25% | 1.23M | $595.58K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATYR
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to FDA in June 2026 for planned Phase 3 stud…
What It Means To Hold Moderna Stock In A Crash
The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available…
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.comNEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today an…
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sa…
aTyr Pharma to Participate in Upcoming Investor Conferences
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today a…
ATYR — Frequently Asked Questions
What is the current share price of aTyr Pharma, Inc. (ATYR)?
As of 2026-07-15 16:51 PDT, aTyr Pharma, Inc. (ATYR) trades at $0.53 on NasdaqCM. Its 52-week range is $0.40 to $6.61.
What is the market capitalisation of ATYR?
aTyr Pharma, Inc. (ATYR) has a market capitalisation of $51.97M on NasdaqCM.
What is the P/E ratio of ATYR?
ATYR trades at a trailing price-to-earnings (P/E) ratio of -0.72. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 0.82.
What is the return on equity (ROE) of ATYR?
ATYR has a return on equity (ROE) of -105.63%. Its return on capital employed (ROCE) is -99.71%.
Is ATYR a good stock to buy?
This page provides a data-driven analysis of aTyr Pharma, Inc. (ATYR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.